CATX · Perspective Therapeutics, Inc.
$2.98
+0.11 (+3.83%)
At close · Jul 30
Market Cap
$327.31M
Shares
114.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.87
Open$2.87
Day$2.77–2.93
52W$1.96–6.16
Avg vol 30d2.1M
Short int22.8M · 20.0% float · 10.0d
Short vol46%
Last earningsJan 13, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−12%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−44%
trailing
YTD return
+4%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
23 of 136 funds reported for Jun 30 · net +147.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.98% of float · ▲ +0.3% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
136 holders — near 2-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
Gross margin
24%
expanding
EPS growth
−14%
Y/Y
Free cash flow
$-95.2M
Balance sheet
$29.0M
net cash
Quant / Vol
risk profile
Volatility
110%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
23 of 136 funds reported for Jun 30 · net +147.7K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.98% of float · ▲ +0.3% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
136 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 22%
52-wk high $6
vs 200-day avg -19%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CATX
this stock
Perspective Therapeutics, Inc.
|
$327.31M | +4.4% | — | — | 20.0% |
|
ABT
Abbott Laboratories
|
$188.12B | -13.4% | +5.7% | 30.3 | 1.4% |
|
SYK
Stryker Corp
|
$133.42B | +0.5% | +11.2% | 40.8 | 1.8% |
|
MDT
Medtronic plc
|
$112.06B | -8.1% | +8.4% | 23.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.37B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CATX | -3.4% | -15.8% | -43.7% | -15.8% | +4.4% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -1.0% | -13.5% | -50.0% | -13.5% | -2.6% |
Key facts
CIK
728387
CUSIP
46489V302
13F (30d)
25 filings
24 filers
Visit website
Investor relations